Cargando…

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant

RATIONALE: Orexins play a key role in the maintenance of alertness and are implicated in the modulation of diverse physiological processes, including cognitive function. Almorexant, a dual orexin receptor antagonist, transiently and reversibly blocks the action of orexin peptides at both OX(1) and O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietrich, Hendrik, Jenck, François
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937139/ https://www.ncbi.nlm.nih.gov/pubmed/20631993 http://dx.doi.org/10.1007/s00213-010-1933-5

Ejemplares similares

The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats
por: Morairty, Stephen R., et al.
Publicado: (2014)

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
por: Dingemanse, Jasper, et al.
Publicado: (2014)

The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the Ventral Tegmental Area Attenuates Ethanol Self-Administration
por: Srinivasan, Subhashini, et al.
Publicado: (2012)

The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
por: Steiner, Michel A., et al.
Publicado: (2013)

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma
por: Dayot, Stéphanie, et al.
Publicado: (2018)

Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise
por: Martin, Tristan, et al.
Publicado: (2019)

Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
por: Patel, Ameera X., et al.
Publicado: (2014)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2017)

Author Correction: Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise
por: Martin, Tristan, et al.
Publicado: (2020)

Correction to: Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2019)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
por: Uchiyama, Makoto, et al.
Publicado: (2022)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Differential sleep-promoting effects of dual orexin receptor antagonists and GABA(A) receptor modulators
por: Gotter, Anthony L, et al.
Publicado: (2014)

Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice
por: Duncan, Marilyn J., et al.
Publicado: (2019)

The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
por: Khoo, Shaun Yon-Seng, et al.
Publicado: (2017)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
por: Zhou, Mengzhen, et al.
Publicado: (2023)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
por: Rocha, Rebeka Bustamante, et al.
Publicado: (2023)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Dual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Rats
por: DeCarlo, Arthur A., et al.
Publicado: (2022)

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
por: Gotter, Anthony L, et al.
Publicado: (2013)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
por: Xue, Tao, et al.
Publicado: (2023)

Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review
por: Besterman, Aaron D., et al.
Publicado: (2021)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
por: Illenberger, Jessica M., et al.
Publicado: (2023)

Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABA(A) and Glutamate Receptors
por: Razavi, Bibi Marjan, et al.
Publicado: (2020)

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists
por: Gozzi, Alessandro, et al.
Publicado: (2011)

The Modulatory Role of Orexin 1 Receptor in CA1 on Orofacial Pain-induced Learning and Memory Deficits in Rats
por: Kooshki, Razieh, et al.
Publicado: (2017)

Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long–Evans rats
por: Richards, Jemma K., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_dsm1bls1tue4pas40b93p3e14r